Latest news with #ClermontFerrand
Yahoo
20-06-2025
- Business
- Yahoo
Carbios presents the results of its Annual General Meeting of 19 June 2025 and the composition of its Board of Directors
Clermont-Ferrand (France), June 20, 2025 (6:45 am CEST). CARBIOS, (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, announces the results of its Ordinary and Extraordinary general Meeting of June 19, 2025. Shareholders physically present, represented or voting by post totalled 31.18% of the shares composing the Company's share capital and carrying voting rights, and 31.25% of the voting rights. All the resolutions on the agenda were approved, excepted the 21st Resolution. It has notably been approved the renewal of the term of office of Business Opportunities for L'Oréal Development (BOLD), Michelin Ventures, Ms Isabelle Parize, Mr Vincent Kamel, Ms Karine Auclair and Mr Mateus Schreiner Garcez Lopes as directors. The detail of shareholders votes at this Meeting will be available on the Company's website at Mr Juan de Pablo and Ms Amandine de Souza have presented their resignations as directors, with effect from the close of the Annual General Meeting of 19 June 2025. Sandrine Conseiller has presented her resignation from her directorship with effect from 20 June 2025. As from 20 June 2025, the Board of Directors will comprise 7 directors, including 3 independent directors (BOLD - Business Opportunities for L'Oréal Development, Michelin Ventures, Ms Isabelle Parize, Mr Vincent Kamel, Ms Jennifer Saenz, Ms Karine Auclair, Mr Mateus Schreiner Garcez Lopes) and one non-voting director (Copernicus Wealth Management). In addition, the co-optation of Ms Julie Sonies as an independent director, to replace Ms Sandrine Conseiller, will be proposed at the next Board meeting scheduled for 1 July 2025. With over 20 years' experience in Finance and Investment Banking, Julie Sonies has forged a remarkable professional career. Graduated from Université Paris Dauphine and holder of a Master's degree in Finance from Science-Po Paris, she has been Chief Financial Officer of Redefine Meat, Managing Director of the Retail & Consumer divisions at UBS and Deutsche Bank in London, Vice-President Consumer & Retail at Goldman Sachs in London and analyst at Merrill Lynch in Paris and London. About CARBIOS: CARBIOS is a biotech company developing and industrializing biological solutions to reinvent the life cycle of plastic and textiles. Inspired by nature, CARBIOS develops enzyme-based processes to break down plastic with a mission to avoid plastic and textile pollution and accelerate the transition to a circular economy. Its two disruptive technologies for the biorecycling of PET and the biodegradation of PLA are reaching industrial and commercial scale. Its biorecycling demonstration plant has been operational since 2021 and construction work of the world's first industrial biorecycling plant is expected to restart in the second half of 2025, subject to the necessary additional funding. CARBIOS has received scientific recognition, notably with the cover of Nature, and is supported by prestigious brands in the cosmetics, Food & Beverage and apparel industries to enhance their products' recyclability and circularity. Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe are members of a packaging consortium founded by CARBIOS and L'Oréal. On, Patagonia, PUMA, PVH Corp. and Salomon collaborate with CARBIOS in a textile consortium. Visit to find out more about biotechnology powering plastic and textile circularity. LinkedIn: CARBIOS / Instagram: insideCarbios Information on CARBIOS shares: ISIN Code FR0011648716Ticker Code Euronext Growth: ALCRBLEI: 969500M2RCIWO4NO5F08 CARBIOS, founded in 2011 by Truffle Capital, is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in CARBIOS in any country. Translation is for information purposes only. In case of discrepancy between the French and the English version of this press release, the French version shall prevail. Disclaimer on forward-looking statements and risk factors: This press release contains forward-looking statements, not historical data, and should not be construed as a guarantee that the facts and data stated will occur. These forward-looking statements are based on data, assumptions and estimates considered reasonable by CARBIOS. CARBIOS operates in a competitive and rapidly evolving environment. It is therefore not in a position to anticipate all risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of a risk or combination of risks could lead to results that differ significantly from those mentioned in any forward-looking statement. Political, economic and budgetary uncertainties in France and Europe may affect the schedule for actual grant payments. CARBIOS draws your attention to the fact that forward-looking statements are in no way a guarantee of its future performance and that its actual financial position, results, cash flows, its partnerships and corporate agreements, and the development of the sector in which CARBIOS operates may differ significantly from those proposed or suggested by the forward-looking statements contained in this document. In addition, even if CARBIOS' financial position, results, cash flows, its partnerships and corporate agreements, and developments in the industry in which it operates are consistent with the forward-looking information contained in this document, such results or developments may not be a reliable indication of CARBIOS' future results or developments. Readers are also advised to carefully consider the risk factors described in the Universal registration document filed with the French Market Authority ('AMF'), as well as in the half-year financial report available free of charge on the Company's website. Should all or any part of these risk factors occur or others, in no case whatsoever will CARBIOS be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages. This information is given only as of the date of this press release. CARBIOS makes no commitment to publish updates to this information or on the assumptions on which it is based, except in accordance with any legal or regulatory obligation applicable to it. For additional information, please contact: CARBIOSLaura PerrinPress +33 (0)6 30 26 50 04Benjamin AudebertInvestor Relationscontact@ (0)4 73 86 51 76 Press Relations (France)IconicAurélie Aknincarbios@ (0)6 68 28 21 78 Press Relations (DACH & UK)MC ServicesAnne Henneckecarbios@ (0)211 529 252 22 Attachment 2025 06 20 _PR_2025 AGM Result & Board compositionSign in to access your portfolio
Yahoo
20-06-2025
- Business
- Yahoo
Carbios presents the results of its Annual General Meeting of 19 June 2025 and the composition of its Board of Directors
Clermont-Ferrand (France), June 20, 2025 (6:45 am CEST). CARBIOS, (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, announces the results of its Ordinary and Extraordinary general Meeting of June 19, 2025. Shareholders physically present, represented or voting by post totalled 31.18% of the shares composing the Company's share capital and carrying voting rights, and 31.25% of the voting rights. All the resolutions on the agenda were approved, excepted the 21st Resolution. It has notably been approved the renewal of the term of office of Business Opportunities for L'Oréal Development (BOLD), Michelin Ventures, Ms Isabelle Parize, Mr Vincent Kamel, Ms Karine Auclair and Mr Mateus Schreiner Garcez Lopes as directors. The detail of shareholders votes at this Meeting will be available on the Company's website at Mr Juan de Pablo and Ms Amandine de Souza have presented their resignations as directors, with effect from the close of the Annual General Meeting of 19 June 2025. Sandrine Conseiller has presented her resignation from her directorship with effect from 20 June 2025. As from 20 June 2025, the Board of Directors will comprise 7 directors, including 3 independent directors (BOLD - Business Opportunities for L'Oréal Development, Michelin Ventures, Ms Isabelle Parize, Mr Vincent Kamel, Ms Jennifer Saenz, Ms Karine Auclair, Mr Mateus Schreiner Garcez Lopes) and one non-voting director (Copernicus Wealth Management). In addition, the co-optation of Ms Julie Sonies as an independent director, to replace Ms Sandrine Conseiller, will be proposed at the next Board meeting scheduled for 1 July 2025. With over 20 years' experience in Finance and Investment Banking, Julie Sonies has forged a remarkable professional career. Graduated from Université Paris Dauphine and holder of a Master's degree in Finance from Science-Po Paris, she has been Chief Financial Officer of Redefine Meat, Managing Director of the Retail & Consumer divisions at UBS and Deutsche Bank in London, Vice-President Consumer & Retail at Goldman Sachs in London and analyst at Merrill Lynch in Paris and London. About CARBIOS: CARBIOS is a biotech company developing and industrializing biological solutions to reinvent the life cycle of plastic and textiles. Inspired by nature, CARBIOS develops enzyme-based processes to break down plastic with a mission to avoid plastic and textile pollution and accelerate the transition to a circular economy. Its two disruptive technologies for the biorecycling of PET and the biodegradation of PLA are reaching industrial and commercial scale. Its biorecycling demonstration plant has been operational since 2021 and construction work of the world's first industrial biorecycling plant is expected to restart in the second half of 2025, subject to the necessary additional funding. CARBIOS has received scientific recognition, notably with the cover of Nature, and is supported by prestigious brands in the cosmetics, Food & Beverage and apparel industries to enhance their products' recyclability and circularity. Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe are members of a packaging consortium founded by CARBIOS and L'Oréal. On, Patagonia, PUMA, PVH Corp. and Salomon collaborate with CARBIOS in a textile consortium. Visit to find out more about biotechnology powering plastic and textile circularity. LinkedIn: CARBIOS / Instagram: insideCarbios Information on CARBIOS shares: ISIN Code FR0011648716Ticker Code Euronext Growth: ALCRBLEI: 969500M2RCIWO4NO5F08 CARBIOS, founded in 2011 by Truffle Capital, is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in CARBIOS in any country. Translation is for information purposes only. In case of discrepancy between the French and the English version of this press release, the French version shall prevail. Disclaimer on forward-looking statements and risk factors: This press release contains forward-looking statements, not historical data, and should not be construed as a guarantee that the facts and data stated will occur. These forward-looking statements are based on data, assumptions and estimates considered reasonable by CARBIOS. CARBIOS operates in a competitive and rapidly evolving environment. It is therefore not in a position to anticipate all risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of a risk or combination of risks could lead to results that differ significantly from those mentioned in any forward-looking statement. Political, economic and budgetary uncertainties in France and Europe may affect the schedule for actual grant payments. CARBIOS draws your attention to the fact that forward-looking statements are in no way a guarantee of its future performance and that its actual financial position, results, cash flows, its partnerships and corporate agreements, and the development of the sector in which CARBIOS operates may differ significantly from those proposed or suggested by the forward-looking statements contained in this document. In addition, even if CARBIOS' financial position, results, cash flows, its partnerships and corporate agreements, and developments in the industry in which it operates are consistent with the forward-looking information contained in this document, such results or developments may not be a reliable indication of CARBIOS' future results or developments. Readers are also advised to carefully consider the risk factors described in the Universal registration document filed with the French Market Authority ('AMF'), as well as in the half-year financial report available free of charge on the Company's website. Should all or any part of these risk factors occur or others, in no case whatsoever will CARBIOS be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages. This information is given only as of the date of this press release. CARBIOS makes no commitment to publish updates to this information or on the assumptions on which it is based, except in accordance with any legal or regulatory obligation applicable to it. For additional information, please contact: CARBIOSLaura PerrinPress +33 (0)6 30 26 50 04Benjamin AudebertInvestor Relationscontact@ (0)4 73 86 51 76 Press Relations (France)IconicAurélie Aknincarbios@ (0)6 68 28 21 78 Press Relations (DACH & UK)MC ServicesAnne Henneckecarbios@ (0)211 529 252 22 Attachment 2025 06 20 _PR_2025 AGM Result & Board compositionError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-06-2025
- Business
- Yahoo
AFYREN Begins New Phase of Industrial Strategy as First Plant AFYREN NEOXY Achieves Continuous Production
AFYREN NEOXY: continuous production achieved and acceleration in commercialization Industrial continuous running1 of all stages of the process validated in recent weeks and start of industrial ramp-up Hundreds of tons of bio-based acids produced and currently being commercialized €165 million in revenue secured by contracts, to be executed in coming years Update on short and medium-term objectives AFYREN NEOXY: objective to achieve significant production revenue in 2025, estimated in the low single-digit million euros range2, and plant break-even3 targeted within a few quarters AFYREN: aims to achieve the goal of building and operating three plants in a sequence manner to better capitalize on the success of AFYREN NEOXY, including intermediary debottlenecking project4 CLERMONT-FERRAND, France & LYON, France, June 17, 2025--(BUSINESS WIRE)--Regulatory News: AFYREN (Paris:ALAFY), a greentech company offering industrial customers bio-based, low-carbon products through its unique fermentation technology based on a circular model, today announced its first plant AFYREN NEOXY has achieved continuous production, enabling the acceleration of commercialization. Nicolas SORDET, CEO AFYREN, declares: "The transition to continuous production at AFYREN NEOXY, the first biorefinery using the AFYREN technology, demonstrates our command of all key stages of an innovative process with no equivalents worldwide. This major success marks the end of an especially demanding period for our teams, whose dedication and resilience I sincerely commend. We are now in the industrial ramp-up phase, enabling us to regularly deliver finished products to our customers in increasing volumes. Building on this success, we are planning to increase our industrial capacity production gradually in coming quarters, in order to better capitalize on AFYREN NEOXY." Continuous production achieved and acceleration in commercialization AFYREN has successfully manufactured hundreds of tons of products in recent weeks, resulting from continuous production at the plant. The bio-based acids produced are currently undergoing qualification prior to delivery, in accordance with the multi-year contracts signed with customers. This major milestone is the culmination of two years of efforts by the AFYREN and AFYREN NEOXY teams to ensure the reliability of the equipment and mastering the operating conditions at industrial scale, ensuring the continuous operation of this unique biorefinery. This milestone marks the beginning of a new phase that will see the gradual ramp-up of AFYREN NEOXY's industrial production to ultimately achieve the targets set in 2021: annual production revenue of around €35 million with a current EBITDA margin of around 25% (equivalent to a current EBITDA of around €9 million) at full capacity (16,000 tons per year). During the ramp-up period, product shipment will be made on a regular basis with priority given to long-term customers. As a reminder, commercial commitments secured through contracts represent cumulative revenue of over €165 million, to be recognized in the upcoming years. These contracts are with leading players in the target markets of human nutrition and feed, flavors and fragrances, life sciences, materials sciences, and lubricants. Update on short and medium-term objectives On this basis, AFYREN NEOXY expects production revenue in 2025 to be in the low single-digit million euros range5. The plant is expected to break even (positive current EBITDA) within a few quarters. In parallel, AFYREN is planning targeted investments to lift bottlenecks6 at the AFYREN NEOXY plant. By doing so, AFYREN would increase production capacity and boost target profitability beyond the previously mentioned objectives. AFYREN's medium-term objectives will be updated to reflect the progress of the AFYREN NEOXY ramp-up. The core operational and financial targets remain unchanged — specifically the plan to build and operate three production sites, generating a combined €150 million in revenue at full capacity7 with a target Group EBITDA margin of around 30%. Instead of adhering strictly to the current target of having three plants installed, of which two in continuous production by 2028, AFYREN is exploring a phased approach. This would allow the company to consolidate the achievements of its first biorefinery and leverage the operational experience gained before moving forward with the development of Plants 2 and 3. This approach will enable the Group to maintain a safe degree of agility and keep good control of AFYREN's cash burn and should enable the financing of future plants under optimized conditions. Stefan BORGAS, Chairman of AFYREN's Board of Directors, added: "The transition to continuous production is a major milestone in AFYREN's history. The Company is joining a very select group of companies that have successfully industrialized a competitive green technology. This is a remarkable achievement in the increasingly demanding and selective chemical industry. It opens up extremely positive prospects for our company in terms of industrial and commercial development." About AFYREN AFYREN is a French greentech company, founded in 2012, focused on providing innovative, sustainable solutions to reduce reliance on fossil-based resources. AFYREN's proprietary, nature-inspired fermentation technology valorizes local biomass from non-food agricultural co-products to produce 100% biobased, low-carbon carboxylic acids. The company's sustainable solutions address decarbonization challenges in a wide variety of strategic sectors, including human and animal nutrition, flavors and fragrances, life sciences, materials science, plus lubricants and technical fluids. AFYREN's competitive, plug-and-play, circular technology enables manufacturers to adopt sustainable solutions without modifying production processes. The company's first industrial plant, AFYREN NEOXY, a joint venture with Bpifrance's SPI fund, is based in the Grand-Est region of France, serving primarily the European market. AFYREN is also pursuing a project in Thailand with a global leader in the sugar industry and is building its presence in the Americas, based on existing distribution agreements. At the end of 2024, AFYREN employed 130 people across sites in Lyon, Clermont-Ferrand and Carling Saint-Avold. Committed to continuous innovation, the company invests 20% of its annual budget in R&D to further develop the range of sustainable solutions. AFYREN is listed on Euronext Growth® Paris since 2021 (ISIN code: FR0014005AC9, ticker: ALAFY). For more information, visit and follow us on LinkedIn. Financial calendar Events Dates Annual General Meeting Tuesday, June 17, 2025, in Lyon 2025 half-year results Thursday, September 25, 2025 1 Simultaneous operation of all stages of the process – from fermentation to finished products, in a stable and repeatable manner2 Projections subject to operational adjustments to be made to increase production rates during the ramp-up phase3 Positive current EBITDA from production4 Removal of capacity bottlenecks identified in the operations chain, enabling increased production capacity and reliability of operations with a higher target profitability for AFYREN NEOXY5 Projections subject to operational adjustments to be made to increase production rates during the ramp-up phase6 Removal of capacity bottlenecks identified in the operations chain, enabling increased production capacity and reliability of operations with a higher target profitability for AFYREN NEOXY7 After a ramp-up period View source version on Contacts AFYRENDirector for ESG, Communications and Public AffairsCaroline Investor RelationsMark Reinhardinvest@ NewCapInvestor RelationsThéo Martin / Mathilde BohinTel: +33 1 44 71 94 94afyren@ Media RelationsNicolas Mérigeau / Gaëlle FromaigeatTel: +33 1 44 71 94 98afyren@ MC Services AG (international)Investor RelationsBettina EllinghorstMedia RelationsShaun Brown, Dr. Johanna KoblerTel: +49 89 210 228 0afyren@ Sign in to access your portfolio
Khaleej Times
27-05-2025
- Entertainment
- Khaleej Times
French documentary filmmaker Marcel Ophuls dead at 97
Oscar-winning filmmaker Marcel Ophuls, who blew the lid off the myth that France resisted its World War II Nazi occupiers in The Sorrow and the Pity, has died aged 97, his family said. Ophuls, who was the son of renowned German Jewish director Max Ophuls, "died peacefully on May 24", his grandson Andreas-Benjamin Seyfert said in a statement. Ophuls rocked France with 1969's The Sorrow and the Pity, about the occupied French provincial city of Clermont Ferrand during the time of the collaborationist Vichy regime. It quietly demolished one of the country's most cherished myths—that France and the French had always resisted the Germans—and was banned from public television until 1981. Through a jigsaw of interviews and newsreels, it showed how collaboration with the Nazis was widespread, from the humblest hairdresser to the top of high society. Ophuls played down his feat, stressing that he was not trying to judge France, and was just working on a TV commission. "For 40 years, I've had to put up with all this bullshit about it being a prosecutorial film. It doesn't attempt to prosecute the French," he insisted. "Who can say their nation would have behaved better in the same circumstances?" he added. Despite being over four hours long, his film struck a chord with a generation, drawing crowds to the cinemas at a time when documentaries were rarely shown on the big screen. Fled Nazis Ophuls was born Hans Marcel Oppenheimer in Frankfurt, Germany on November 1, 1927, to German actress Hilde Wall and director Max Ophuls. He fled for France with his father and the film directors Billy Wilder and Fritz Lang, before escaping across the Pyrenees mountains and arriving in the US in 1941. He grew up in Hollywood, going on to serve as a GI in Japan in 1946. Returning to France in 1950, he started out as an assistant director, working on his father's last film Lola Montes in 1955. He made an unsuccessful entry into fiction with Banana Skin in 1963, starring the star duo of Jean-Paul Belmondo and Jeanne Moreau, before shifting to documentary when hired by French public television. Hotel Terminus - The Life and Times of Klaus Barbie won him an Oscar for best documentary in 1989. But his 1994 documentary The Troubles We've Seen, about war reporting in Bosnia, was a commercial flop. He spent several years afterwards holed up in southern France not working. His return with Un voyageur, a travelogue, in 2013, packed the cinema at the Cannes Film Festival. He was philosophical about the influence of his father. "It helped me to get work. More than anything, it helped me to be modest about my achievements. I was born under the shadow of a genius, and that spared me from being vain," he said.
Yahoo
27-05-2025
- Business
- Yahoo
AFYREN Achieves "Responsible Care® Confirmed Diagnosis" Certification and Published Its Second Sustainability Report
AFYREN confirms its proactive approach to Corporate Social Responsibility (CSR) with: the award of the "Responsible Care® - Confirmed Diagnosis" certificate by France Chimie for its AFYREN NEOXY industrial site the publication of its second sustainability report, structured in accordance with the requirements of the CSR directive (CSRD) CLERMONT-FERRAND, France & LYON, France, May 27, 2025--(BUSINESS WIRE)--Regulatory News: AFYREN (Euronext: FR0014005AC9 - ALAFY), a greentech company offering industrial customers bio-based, low-carbon products through a unique fermentation technology based on a circular model, announces that it has received the "Responsible Care® - Confirmed Diagnosis" certification from France Chimie for its AFYREN NEOXY industrial site. AFYREN has also published its sustainability report for the 2024 financial year. In order to strengthen stakeholder recognition of its CSR approach, the company decided to undergo an external review by "Responsible Care® - Confirmed Diagnosis", led by France Chimie, in accordance with the CSR framework for the global chemical industry. This certification reflects the growing structure of AFYREN's CSR policy, marked in 2024 by the signing of the Responsible Care® charter by the management team of AFYREN and AFYREN NEOXY. Responsible Care is the global chemical industry's voluntary initiative for the safe management of chemicals and a shared commitment to continuously improve health, safety, and environmental performance through ethical practices, transparent communication, and sustainable innovation. Led jointly by the QHSE (Quality, Health, Safety, and Environment) and CSR teams, the assessment, which took several months and included around 20 interviews with various departments within the company, resulted in the development of a realistic and ambitious CSR roadmap incorporating concrete actions plus short- and medium-term deadlines tailored to the company's specific characteristics. "The external perspective and action plan developed by the Confirmed Diagnostic support enabled us to prioritize the actions to be taken and strengthen our preparation for upcoming certifications. The particular attention paid to monitoring product quality is in line with our commitment to better serving our customers" explains Sabine DOSSAT, QHSE Manager at AFYREN. The Responsible Care® diagnosis also highlighted AFYREN's pioneering role in non-financial communication, particularly its voluntary reporting approach. In line with its stated commitment to transparent communication on its commitments, AFYREN is publishing its second sustainability report in accordance with the nature and framework proposed by the CSR Directive. This report traces the company's progress, incorporating new performance indicators and examples of concrete actions. This report is part of AFYREN's ongoing commitment to improving its CSR performance, as confirmed by the positive trend in the Company's non-financial ratings over the past five years. Caroline PETIGNY, Director of CSR, Communications and Public Affairs at AFYREN states: "We have very high standards in terms of CSR, and our model is centered on responsible governance, limited environmental impact, and a strong social commitment to serving a robust and resilient industry. This requirement involves transparency about our commitments and our drivers for improvement. We see CSR reporting as a powerful tool for mobilizing teams, ensuring accountability, engaging with our stakeholders, and promoting the company's actions. The CSR approach is of great significance for our Company that we will continue to develop in the years ahead." The sustainability report can be viewed and downloaded in a dedicated section of the company's website: About AFYREN AFYREN is a French greentech company, founded in 2012, focused on providing innovative, sustainable solutions to reduce reliance on fossil-based resources. AFYREN's proprietary, nature-inspired fermentation technology valorizes local biomass from non-food agricultural co-products to produce 100% biobased, low-carbon carboxylic acids. The company's sustainable solutions address decarbonization challenges in a wide variety of strategic sectors, including human and animal nutrition, flavors and fragrances, life sciences, materials science, plus lubricants and technical fluids. AFYREN's competitive, plug-and-play, circular technology enables manufacturers to adopt sustainable solutions without modifying production processes. The company's first industrial plant, AFYREN NEOXY, a joint venture with Bpifrance's SPI fund, is based in the Grand-Est region of France, serving primarily the European market. AFYREN is also pursuing a project in Thailand with a global leader in the sugar industry and is building its presence in the Americas, based on existing distribution agreements. At the end of 2024, AFYREN employed 130 people across sites in Lyon, Clermont-Ferrand and Carling Saint-Avold. Committed to continuous innovation, the company invests 20% of its annual budget in R&D to further develop the range of sustainable solutions. AFYREN is listed on Euronext Growth® Paris since 2021 (ISIN code: FR0014005AC9, ticker: ALAFY). For more information, visit and follow us on LinkedIn View source version on Contacts AFYREN Director for ESG, Communications and Public Affairs Caroline Investor Relations Mark Reinhardinvest@ NewCap Investor Relations Théo Martin / Mathilde BohinTel: +33 1 44 71 94 94afyren@ Media Relations Nicolas Mérigeau / Gaëlle FromaigeatTel: +33 1 44 71 94 98afyren@ MC Services AG (international) Investor Relations Bettina Ellinghorst Media Relations Dr. Johanna Kobler, Shaun Brown Tel: +49 89 210 228 0afyren@
